Tracers / [203Pb]eSOMA-03

[203Pb]eSOMA-03

Radionuclide: Pb-203
Modality: Therapy
Production route: —
Stage: Reported once
Syntheses indexed: 1

What it is

Compound class: Octreotate-based somatostatin receptor peptide ligand (eSOMA-03)
Target / mechanism: Somatostatin receptor type 2 (SSTR2) binding via octreotate-based ligand PMID 37513897
Clinical application: Neuroendocrine tumors (NETs) PMID 37513897
Theranostic pair: —

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	none	≥96%	≥95%	eSOMA-03	37513897 2023 Pharmaceuticals (Basel) [203Pb]PbCl2 (40 MBq) in 0.5 M HCl ... was added to a mixture of DOTAM-TATE or eSOMA-(01-03) (1 nmol), ascorbic acid/gentisic acid (10 μL, 50 mM), sodium acetate (30 μL, 2.5 M), and H2O (final volume of 140 μL). The mixture was incubated for 20 min at rt. — All labeled compounds were obtained with a RCY ≥ 96% and a RCP ≥ 95%.

Need this precursor?We can point you to suppliers for [203Pb]eSOMA-03, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 37513897. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 37513897: 'DOTAM-TATE or eSOMA-(01-03)'.